Výsledky vyhľadávania - "DOLUTEGRAVIR"

Understanding causes of incomplete reports of adverse drug reactions associated with dolutegravir-based HIV treatment in uganda: a qualitative study.

Autori: Zakumumpa, Henry Ndagije, Helen Byomire Atuhaire, Joanitah a ďalší

Zdroj: BMC Infectious Diseases. 11/3/2025, Vol. 25 Issue 1, p1-14. 14p.

Predmety: *DOLUTEGRAVIR, *DRUG side effects, *QUALITATIVE research, *AIDS treatment, *PUBLIC health infrastructure, *DRUG utilization, *DATA integrity

Geografický termín: UGANDA

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083 Open Access.

Autori: Moore, Hannah P Fogel, Jessica M Marzinke, Mark A a ďalší

Zdroj: Open Forum Infectious Diseases. Nov2025, Vol. 12 Issue 11, p1-6. 6p.

Predmety: *HIV, *DOLUTEGRAVIR, *TENOFOVIR, *LAMIVUDINE, *CLINICAL drug trials, *MEDICAL research, *VIRAL load, *INTEGRASE inhibitors

Two or Three? Clinical and Proteomic Perspectives on Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV Treatment Open Access.

Autori: Díaz-García, Claudio Serrano-Villar, Sergio Morales, Alejandro G. García-Ruiz de a ďalší

Zdroj: Open Forum Infectious Diseases. Nov2025, Vol. 12 Issue 11, p1-9. 9p.

Predmety: *DOLUTEGRAVIR, *LAMIVUDINE, *PROTEOMICS, *ANTIRETROVIRAL agents, *DRUGS, *AIDS treatment, *EMTRICITABINE

Dolutegravir with enteral feeds in intensive care: Case series with therapeutic drug monitoring.

Autori: Leung, Suki Temple, Adam Al‐Shakarchi, Yaser a ďalší

Zdroj: British Journal of Clinical Pharmacology. Nov2025, Vol. 91 Issue 11, p3272-3278. 7p.

Predmety: *DOLUTEGRAVIR, *HIV, *TUBE feeding, *CRITICALLY ill, *DRUG absorption, *PHARMACOKINETICS, *CRITICAL care medicine, *DRUG monitoring

Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort Open Access.

Autori: Vergori, Alessandra Cozzi-Lepri, Alessandro Caputo, Sergio Lo a ďalší

Zdroj: Journal of Antimicrobial Chemotherapy (JAC). Nov2025, Vol. 80 Issue 11, p3082-3091. 10p.

Predmety: *HIV, *DOLUTEGRAVIR, *EMPIRICAL research, *TREATMENT failure, *LAMIVUDINE, *ANTIRETROVIRAL agents

Correlates of virological non-suppression among children and adolescents aged 5–19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study.

Autori: Moro, Vincent Okech Ssenkusu, John Mbaziira Kiweewa, Flavia Matovu

Zdroj: BMC Infectious Diseases. 10/29/2025, Vol. 25 Issue 1, p1-29. 29p.

Predmety: *DOLUTEGRAVIR, *AIDS treatment, *MALNUTRITION, *SCHOOL children, *TEENAGERS, *MIXED methods research, *VIRAL replication

Geografický termín: UGANDA

Fetal Defects in Mice Treated With Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir, and Cabotegravir.

Autori: Mohan, Haneesha Nguyen, Jessica Yee, Audrey a ďalší

Zdroj: Journal of Infectious Diseases. 10/15/2025, Vol. 232 Issue 4, p847-858. 12p.

Predmety: *FETAL abnormalities, *DOLUTEGRAVIR, *RALTEGRAVIR, *PREGNANCY outcomes, *HIV integrase inhibitors, *AIDS treatment, *INTEGRASE inhibitors, *ANTI-HIV agents

Clinical outcomes of dolutegravir treatment in people living with HIV in Brazil: protocol for the CODE cohort.

Autori: Brites, Carlos Luz, Estela Stelitano, Cristiani a ďalší

Zdroj: BMC Infectious Diseases. 10/8/2025, Vol. 25 Issue 1, p1-9. 9p.

Predmety: *HIV, *DOLUTEGRAVIR, *PATIENT safety, *MEDICAL research, *ANTIRETROVIRAL agents, *VIRAL replication

Geografický termín: BRAZIL

Antiretroviral Therapy Intensification With Dolutegravir and/or Maraviroc Did Not Affect HIV-1 Cell-Associated DNA, RNA, and 2-–LTR Circles Over 12 Weeks Open Access.

Autori: Reed, Jonathan C Hall, Luke McKhann, Ashley a ďalší

Zdroj: Open Forum Infectious Diseases. Oct2025, Vol. 12 Issue 10, p1-10. 10p.

Predmety: *DOLUTEGRAVIR, *HIV, *ANTIRETROVIRAL agents, *RNA, *CLINICAL trials, *NEUROBEHAVIORAL disorders

Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe.

Autori: Washaya, Tendai Chimukangara, Benjamin Mayini, Justin a ďalší

Zdroj: Viruses (1999-4915). Oct2025, Vol. 17 Issue 10, p1348. 13p.

Predmety: *DRUG resistance, *DOLUTEGRAVIR, *MULTIDRUG resistance, *HIV, *INTEGRASES, *TREATMENT failure, *ANTIRETROVIRAL agents

Geografický termín: AFRICA, ZIMBABWE

Dolutegravir Resistance in Mozambique: Insights from a Programmatic HIV Resistance Testing Intervention in a Highly Antiretroviral Therapy-Experienced Cohort.

Autori: Ruano, Maria Flores, Antonio Couto, Aleny a ďalší

Zdroj: Infectious Disease Reports. Oct2025, Vol. 17 Issue 5, p123. 14p.

Predmety: *DOLUTEGRAVIR, *DRUG resistance, *PUBLIC health, *ANTIRETROVIRAL agents, *GENETIC testing

Geografický termín: MOZAMBIQUE

Korporácia: MEDECINS Sans Frontieres (Association)

Nose-to-Brain Delivery of Dolutegravir via Thermoresponsive Nanostructured Lipid Carriers: Cytocompatibility and Fluorescent Biodistribution Studies.

Autori: Taher, Salam Shanta Al-Kinani, Khalid Kadhem

Zdroj: Journal of Nanostructures. Autumn2025, Vol. 15 Issue 4, p2227-2236. 10p.

Predmety: *DOLUTEGRAVIR, *INTRANASAL administration, *CYTOCOMPATIBILITY, *NANOCARRIERS, *BLOOD-brain barrier, *NEUROLOGICAL disorders, *FLUOROPHORES

HIV Dolutegravir resistance and multiclass failure in Mozambique: findings from a real-world cohort.

Autori: Ciccacci, Fausto Doro Altan, Anna Maria Majid, Noorjehan a ďalší

Zdroj: BMC Infectious Diseases. 9/29/2025, Vol. 25 Issue 1, p1-8. 8p.

Predmety: *DOLUTEGRAVIR, *MULTIDRUG resistance, *COHORT analysis, *ANTIRETROVIRAL agents, *HIV

Geografický termín: AFRICA, MOZAMBIQUE

Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation.

Autori: Zheng, Amy Brennan, Alana T. Greener, Ross a ďalší

Zdroj: Infectious Diseases. Sep2025, p1-11. 11p. 4 Illustrations.

Predmety: *DOLUTEGRAVIR, *EFAVIRENZ, *HIV, *SIMULATION methods & models, *ANTIRETROVIRAL agents, *VIRAL replication, *APPLIED sciences

Geografický termín: SUB-Saharan Africa, SOUTH Africa, JOHANNESBURG (South Africa)

INFLAMMATORY CYTOKINES AND CD4 COUNTS IN HIV PATIENTS ON DOLUTEGRAVIR-BASED THERAPY: A SCOPING REVIEW.

Autori: OLI, A. H. MADUKA, H. C. C. MADUKA, I. C. a ďalší

Zdroj: Journal of Pharmaceutical & Allied Sciences. 2025, Vol. 22 Issue 4, p4910-4922. 13p.

Predmety: *HIV, *DOLUTEGRAVIR, *T helper cells, *INTERLEUKIN-10, *CYTOKINES, *TUMOR necrosis factors, *ANTIRETROVIRAL agents, *IMMUNE reconstitution inflammatory syndrome

Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO Registry.

Autori: Lagi, Filippo Bellomo, Michele Lolatto, Riccardo a ďalší

Zdroj: Viruses (1999-4915). Sep2025, Vol. 17 Issue 9, p1158. 11p.

Predmety: *DOLUTEGRAVIR, *DARUNAVIR, *MEDICAL registry personnel, *TREATMENT effectiveness, *EMPIRICAL research, *TREATMENT failure, *ANTIRETROVIRAL agents

Uptake and 24-month Outcomes of Dolutegravir- Versus Lopinavir-based Second-line Antiretroviral Therapy for People With HIV in South Africa: A Retrospective Cohort Study and Emulated Target Trial Open Access.

Autori: Brown, Jennifer Anne Lewis, Lara Sookrajh, Yukteshwar a ďalší

Zdroj: Open Forum Infectious Diseases. Sep2025, Vol. 12 Issue 9, p1-9. 9p.

Predmety: *DOLUTEGRAVIR, *LOPINAVIR-ritonavir, *VIREMIA, *TREATMENT effectiveness, *HIV, *SOUTH Africans, *ANTIRETROVIRAL agents, *COHORT analysis

Geografický termín: SOUTH Africa, KWAZULU-Natal (South Africa)

Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti Open Access.

Autori: Liautaud, Bernard Chico, Ana Sanchez Macius, Youry a ďalší

Zdroj: Open Forum Infectious Diseases. Sep2025, Vol. 12 Issue 9, p1-9. 9p.

Predmety: *HIV, *DOLUTEGRAVIR, *SOCIAL unrest, *TENOFOVIR, *TREATMENT effectiveness, *THERAPEUTICS, *LAMIVUDINE, *HAITIANS

Geografický termín: HAITI

Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia.

Autori: Pane, Meivina Ramadhani Yunihastuti, Evy Putranto, Rudi a ďalší

Zdroj: Scientific Reports. 8/12/2025, Vol. 15 Issue 1, p1-9. 9p.

Predmety: *QUALITY of life, *DOLUTEGRAVIR, *HIV, *NEVIRAPINE, *COHORT analysis, *INDONESIANS, *TREATMENT effectiveness, *ANTIRETROVIRAL agents

Geografický termín: INDONESIA

Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital.

Autori: Abraham, Firew Toma, Alemayehu Balcha, Tamrat a ďalší

Zdroj: Scientific Reports. 8/5/2025, Vol. 15 Issue 1, p1-10. 10p.

Predmety: *DOLUTEGRAVIR, *LIVER enzymes, *HEPATOTOXICOLOGY, *HIV-positive persons, *ANTIRETROVIRAL agents, *OBSTRUCTIVE jaundice, *DISEASE risk factors

Geografický termín: ETHIOPIA